Ocugen (OCGN) Has A Healthy Cash Position For 2026 [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
Now . Ocugen, Inc. (NASDAQ:OCGN) released its fourth-quarter fiscal 2025 results on March 4. The company reported research and development expenses of $10.7 million for the quarter. General and administrative costs came in at $6.1 million. For the quarter, net loss per common share reached $0.06. Research and development expenses for the full year totalled $39.8 million, while general and administrative expenses were $27.6 million. Net loss per share for the year was reported at $0.23. Ocugen, Inc. (NASDAQ:OCGN) also stated that its cash and cash equivalents are expected to support operations into the fourth quarter of 2026. A possible extension into the second quarter of 2027 could be achieved if warrants are exercised. The company reaffirmed its target of filing three Biologics License Applications (BLAs) over the next three years. According to the CEO, Shankar Musunuri, Ocugen, Inc. (NASDAQ:OCGN) remains on track to begin a rolling BLA submission in the third quarter of 2026, w
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
- Ocugen (OCGN) had its price target raised by HC Wainwright from $7.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript [Seeking Alpha]Seeking Alpha
- Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewswire
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/24/26 - Form 8-K
- 3/20/26 - Form 8-K
- 3/5/26 - Form 3
- OCGN's page on the SEC website